Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Infliximab Inhibits Activ… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Infliximab Inhibits Activation and Effector Functions of Peripheral Blood T Cells in vitro from Patients with Clinically Active Ulcerative Colitis

Artikel i vetenskaplig tidskrift
Författare Rahil Dahlén
Hans Strid
Anna Lundgren
Stefan Isaksson
Sukanya Raghavan
Maria K Magnusson
Magnus Simrén
Henrik Sjövall
Lena Öhman
Publicerad i Scandinavian Journal of Immunology
Volym 78
Nummer/häfte 3
Sidor 275-284
ISSN 0300-9475
Publiceringsår 2013
Publicerad vid Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi
Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition
Sidor 275-284
Språk en
Länkar dx.doi.org/10.1111/sji.12081
Ämnesord Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal, pharmacology, therapeutic use, Antibodies, Monoclonal, pharmacology, therapeutic use, Apoptosis, drug effects, CD4-Positive T-Lymphocytes, drug effects, immunology, CD8-Positive T-Lymphocytes, drug effects, immunology, Cell Proliferation, drug effects, Colitis, Ulcerative, drug therapy, immunology, metabolism, Female, Forkhead Transcription Factors, metabolism, Granzymes, secretion, Humans, Interferon-gamma, secretion, Interleukin-13, secretion, Interleukin-17, secretion, Interleukin-2 Receptor alpha Subunit, metabolism, Lymphocyte Activation, drug effects, Male, Middle Aged, Tumor Necrosis Factors, secretion, Young Adult
Ämneskategorier Gastroenterologi, Immunologi inom det medicinska området

Sammanfattning

Many patients with inflammatory bowel disease (IBD) are undergoing therapy with infliximab, an antibody specific for TNF. However, the exact mechanisms of action of infliximab are not completely understood. The aim of this study was to determine the in vitro effects of infliximab on blood T cells derived from anti-TNF therapy-naive ulcerative colitis (UC) patients with clinically active disease. Peripheral blood mononuclear cells were stimulated polyclonally or by antigen in the presence or absence of infliximab. The T cell phenotype was investigated by flow cytometry, cytokine secretion was determined by ELISA, and cell proliferation was determined by thymidine assay or CFSE dye. Presence of infliximab resulted in reduced expression of CD25 in CD4(+) and CD8(+) T cell populations and inhibited secretion of IFN-, IL-13, IL-17A, TNF as well as granzyme A. Infliximab also suppressed CD4(+) and CD8(+) T cell proliferation. These effects of infliximab were recorded both in T cells activated by polyclonal and antigen-specific stimulation. The effects of infliximab on T cell apoptosis and induction of FOXP3(+)CD4(+) T regulatory cells were ambiguous and depended on the originating cellular source and/or the stimulation mode and strength. In conclusion, infliximab is able to reduce T cell activation as measured by CD25, proliferation and cytokine secretion in vitro from UC patients with clinically active disease. These data suggest that suppression of T cell activity may be important for infliximab-mediated disease remission in patients with UC.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?